ImmunoPrecise adds next-gen antibody discovery tech with ModiQuest purchase

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Svisio)
(Image: Getty/Svisio)
ImmunoPrecise Antibodies has acquired ModiQuest Research BV to create a “single source provider of services across the full antibody discovery value chain,” says CRO.

ImmunoPrecise is a contract research organization (CRO) providing therapeutic antibody discovery services. Last week, the Canadian company announced its acquisition of ModiQuest, a custom antibody generation and development provider.

With all related, core activities to be conducted under one company, ImmunoPrecise will offer an increased variety of therapeutically-focused methods of immunization and antigen design, according to the company.

Services include genetic immunization with multiplexed screening, B-cell screening and sorting technologies, antibody expression, stable cell line development, and lead selection, among others.

“Our acquisition of ModiQuest confirms our commitment to excellence as a CRO focused on the next generation of antibody discovery,”​ said Jennifer Bath, PhD, ImmunoPrecise CEO, in a press release.

“The acquisition is immediately accretive and will have a positive impact on consolidated revenues and earnings in the near future,”​ she added.

With The Netherlands-based ModiQuest, European operations now account for approximately 66% of ImmunoPrecise’s corporate revenues.

ImmunoPrecise acquired ModiQuest and its sister entity, Immulease BV – a holding company owning research equipment used in ModiQuest’s operations – for €7m (C$11.2m).

The company has also completed a previously announced non-convertible debenture financing in the amount of approximately C$4m.

The acquisition is anticipated to create annualized revenues of between C$3.5m and C$4.5m for fiscal 2019. Anticipated accretive annualized EBITDA is between C$750,000 and C$850,000 for the same time period.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more